hBChE [human BChE (butyrylcholinesterase)] naturally scavenges OPs (organophosphates). This bioscavenger is currently in Clinical Phase I for pretreatment of OP intoxication. Phosphylated ChEs (cholinesterases) can undergo a spontaneous time-dependent process called 'aging' during which the conjugate is dealkylated, leading to creation of an enzyme that cannot be reactivated. hBChE inhibited by phosphoramidates such as tabun displays a peculiar resistance to oxime-mediated reactivation. We investigated the basis of oxime resistance of phosphoramidylBChE conjugates by determining the kinetics of inhibition, reac-
INTRODUCTION
Human plasma BChE (butyrylcholinesterase; EC 3.1.1.8) is a toxicologically relevant enzyme because it hydrolyses or scavenges a wide range of toxic esters, including heroin, cocaine, carbamate pesticides, organophosphorus pesticides and nerve agents [1, 2] . OPs (organophosphates) exert their acute toxicity through inhibition of AChE (acetylcholinesterase; E.C. 3.1.1.7) by phosphylation of the catalytic serine [2] . Subsequent accumulation of acetylcholine at neuronal synapses and neuromuscular junctions results in paralysis, seizures and other symptoms of cholinergic syndrome [3, 4] . hBChE (human BChE) is a potential drug candidate that may be employed in several therapeutic fields. This is due to the unique structure of the enzyme that allows accommodation of a large variety of substrates and inhibitors, some of which are excluded from the catalytic gorge of acetylcholinesterase [5] . BChE-based biopharmaceuticals are under research and development as stoichiometric and catalytic bioscavengers for neutralization or detoxification of poisonous esters. Recombinant and plasma-purified hBChEs are in Clinical Phase I as the first stoichiometric bioscavengers for the pretreatment of OP intoxication. In case of intoxication, reactivation of hBChE used in pretreatment will improve protection against high dose or repetitive OP exposure. For this reason, it is essential to design efficient reactivators for hBChE.
Phosphylated ChEs (cholinesterases) can be reactivated by specific nucleophiles such as oximes [6, 7] . The most effective oximes used for emergency treatment of nerve agent poisoning are the monopyridinium oximes (2-PAM) and bispyridinium oximes (TMB-4 [1,3-trimethylene-bis(4-hydroxyiminomethylpyridinium) dibromide], MMB-4 {1,1 -methylenebis [4-(hydroxyimino) methyl]pyridinium dibromide}, obidoxime {1,1 -(oxybis-methylene) bis [4-(hydroxyimino) methyl] pyridinium dichloride}, HI-6 {1-[[ [4-(aminocarbonyl) [4-(aminocarbonyl) pyridinio]methoxy]methyl]-2,4-bis-[(hydroxyimino)methyl] pyridinium dimethanesulfonate)}) [6] . Kinetic analysis of the interactions between different AChE-OP conjugates and different oximes shows that the most effective oximes are HLö 7 for phosphonylated AChE and obidoxime for phosphorylated AChE [6] . Unfortunately, a universal antidote, efficient against all nerve Abbreviations used: AChE, acetylcholinesterase; BChE, butyrylcholinesterase; BTCh, butyrylthiocholine; ChE, cholinesterase; DTNB, 5, 5 -dithiobis-(2-nitrobenzoic-acid); hBChE, human BChE; HI-6, 1-[[ [4-(aminocarbonyl) [4-(hydroxyimino) methyl] pyridinium dichloride; OP, organophosphate; TMB-4, 1,3-trimethylene-bis(4-hydroxyiminomethylpyridinium) dibromide. 1 To whom correspondence should be addressed (email fnachon@crssa.net). agents and capable of crossing the blood brain barrier, is not yet available.
Reactivation of inhibited ChEs is complicated by a side reaction. Indeed, phosphylated ChEs undergo a spontaneous, time-dependent process called 'aging' during which the OPChE conjugates are O-dealkylated, leading to non-reactivatable enzyme [8] [9] [10] .
Inhibition of BChE by tabun and the subsequent aging reaction of adducts are of interest, because tabun-ChE conjugates are particularly resistant to most oxime reactivators. Recent studies detail the mode of interaction of tabun with ChEs and show that tabun-ChE conjugates age through O-dealkylation [11] . An extension of this study to various phosphoramidate anologues of tabun provides the basis of a structure-activity relationship analysis of phosphoramidate adducts. The analogues of tabun differ in their amino substituents (Figure 1 ). The reactivation of hBChE inhibited by tabun and its analogues was studied with obidoxime, TMB-4, HI-6 and HLö 7 ( Figure 2) . This study provides a better understanding of the resistance of phosphoramidate-hBChE conjugates to oximes and gives some insights into the design of new oximes capable of reactivating tabun-ChE conjugates, and ChEs inhibited by related agents.
MATERIAL AND METHODS

Materials
DTNB (5,5 -dithio-bis-2-nitrobenzoic acid) and TMB-4 dibromide were obtained from Sigma Chemical Co. Obidoxime dichloride was purchased from Duphar. HI-6 dichloride was kindly provided by Dr J. G. Clement (Defence Research and Development Canada, Suffield, Canada) and HLö-7 dimethanesulfonate was a custom synthesis by Dr J. Braxmeier (Chemisches Labor, Döpshofen, Germany). Tabun and its analogues (TA 1-6) (> 98 % by GC-MS, 1 H-NMR and 31 P-NMR) were made available by the German Ministry of Defence, all other chemicals were from Merck Eurolab GmbH. BTCh (butyrylthiocholine, in the form of S-butyrylthiocholine iodide) was obtained from Sigma.
Stock solutions of tabun and compounds 1-6 (1 % v/v; Figure 1 ) were prepared in propan-2-ol, stored at 4
• C and were appropriately diluted in distilled water just before the experiment. Oximes (200 mM) were prepared in distilled water, stored at − 60
• C and diluted as required in distilled water on the day of the experiment. Human plasma was obtained from heparinized whole blood by centrifugation (1000 g, 10 min, 4
• C) and was stored in aliquots at − 60
• C until use. Research was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association and with national law. Written informed consent was obtained from all blood donors.
Isolated plasma hBChE
Isolated hBChE (E.C. 3.1.1.8) was obtained from Sigma. This enzyme was used for kinetic assays.
Production of recombinant hBChE
Recombinant hBChE was produced in CHO (Chinese hamster ovary) cells and secreted into serum-free culture medium [12] . Briefly, recombinant hBChE was a truncated monomer containing residues 1-529, where the tetramerization domain at the C-terminus was deleted. The glycan chain number was reduced by site-directed mutagenesis from 9 to 6. Enzyme purification was implemented by affinity and ion-exchange chromatography as described in [12] . The active-site concentration of highly purified enzyme was determined using diisopropyl fluorophosphate as the titrant as described [13] . This enzyme was used for crystallographic assays and for testing of enantioselectivity.
Enzyme assays
hBChE activities were measured spectrophotometrically (Cary 3Bio, Varian, Darmstadt, Germany) at 436 nm with a modified Ellman assay at 37
• C [14, 15] . However, the regular Ellman assay at 412 nm works as well. The assay mixture (3.16 ml) contained 1 mM BTCh as substrate and 0.3 mM DTNB as chromogen in 0.1 M phosphate buffer (pH 7.4).
Determination of inhibition rate constants (k i )
The inhibition rate constants were determined at pseudo-firstorder reaction conditions as described previously [6] . In brief, appropriately diluted OP was added to temperature-equilibrated (37
• C) isolated hBChE at t = 0, an aliquot was removed after specified time intervals (1-9 min) and transferred to a cuvette for the determination of residual hBChE activity. k i was calculated from eqn (1): Determination of inhibition enantioselectivity of recombinant hBChE was performed under second-order conditions as described [11] . Briefly, incubation was performed at 25
• C in 50 mM sodium phosphate buffer, pH 7.0, containing 5 % propan-2-ol, 1 mg/ml BSA, a concentration of hBChE of approx. 30 nM, whereas that of tabun analogues ranged between 15 and 200 nM. Residual activity was monitored at 25
• C and pH 7.0, according to Ellman's method using 1 mM BTCh and 0.5 mM DTNB. Under second order conditions, the concentration of residual active enzyme follows eqn 2, as a function of time [11] :
where E is the concentration of residual active enzyme at time t, E 0 the initial concentration of active enzyme, [OP 0 ] the initial concentration of racemic OP, n the number of enantiomers, and ki the bimolecular rate constant of the most active enantiomer assuming the inhibition rate of the other enantiomer is negligible. Analysis of the kinetic data was performed using GOSA-fit, a fitting software based on a simulated annealing algorithm (BioLog, Toulouse, France; http://www.bio-log.biz), allowing simultaneous fitting of all the data at once.
Oxime screening for the reactivation of OP-inhibited hBChE
Human plasma was incubated with a small volume (1 % v/v) of appropriate concentrations of tabun and compounds TA 1-6 for 30 min at 37 • C to achieve an hBChE inhibition of > 90 %. Thereafter, the treated samples were dialysed (phosphate buffer, 0.1 M, pH 7.4) overnight at 4
• C to remove residual inhibitor. The inhibitory activity of the samples was tested by 30 min of incubation at 37
• C of treated plasma and control hBChE in order to verify the absence of residual inhibitor. OP-inhibited hBChE was incubated at 37
• C with 1 mM obidoxime, TMB-4, HI-6 or HLö 7 and the hBChE activity was measured at specified time intervals (1-120 min). Enzyme activities were referred to control activity and the percentage reactivation was calculated according to de Jong and Wolring [16] . Experiments were performed in duplicate.
Kinetics of obidoxime reactivation
Owing to low reactivating potency, the reactivation kinetics were determined at 37
• C by a discontinuous procedure as described previously [6, 17] , which allowed the use of high obidoxime concentrations in the incubation mixture (up to 5 mM). OP-inhibited hBChE was incubated with different obidoxime concentrations and 1 mM BTCh. Aliquots were transferred to cuvettes after specified time intervals (2-45 min) for measurement of hBChE activity. The dissociation constant K d of the enzymeobidoxime complex, the reactivity rate constant k r and the second order reactivation rate constant k r2 were calculated by a standard procedure [6] . Eight to ten obidoxime concentrations, 100-5000 μM with tabun-and TA3-inhibited BChE and 50-3000 μM with TA4-6-inhibited enzyme, were used for the determination of reactivation rate constants.
Determination of rate constants for aging (k a ) and spontaneous reactivation (k s )
OP-inhibited hBChE was brought to 37
• C (t = 0). Then, aliquots were taken after various time intervals for determination of BChE activity (spontaneous reactivation) and of the decrease of oxime-induced reactivation (aging). Next, small aliquots were incubated for 1 h with 1 mM obidoxime. Data from duplicate experiments were referred to control activities and the percentage reactivation was calculated. The pseudo-first-order rate constants k s (spontaneous reactivation) and k a (aging) were calculated using a non-linear regression model [6] .
Crystallization of non-aged TA1, TA4, TA5 and TA6-inhibited hBChE
The buffer used was 0.1 M Mes, pH 6.5, with 2.1 M ammonium sulfate. Stock solutions of tabun analogues were 10 mM in propan-2-ol. Native enzyme was crystallized using the hanging drop method [12] . Crystals grew in 1 week at 20
• C. Then, the OPhBChE conjugates were prepared by soaking crystals for 10 min in 0.1 M Mes buffer, pH 6.5, with 2.1 M ammonium sulfate, containing 2 mM tabun analogue. The crystals were washed with a cryoprotectant solution (0.1 M Mes buffer with 2.1 M ammonium sulfate, containing 20 % glycerol), and then flash-cooled in liquid nitrogen.
Crystallization of aged TA1, TA4 and TA5-hBChE
Purified enzyme (9 mg/ml) was inhibited by 2 mM tabun analogue compounds, in 10 mM Tris/HCl buffer, pH 7.4. The inhibited enzyme was crystallized using the hanging drop method [12] . Crystals grew in 1 week at 20
• C. The time between phosphylation and data collection was sufficiently long (> 2 weeks) to achieve completion of the aging reaction (aging half time < 70 h).
X-ray data collection and structure solution of hBChE
Diffraction data were collected at λ = 0.932 Å (1 Å = 0.1 nm) wavelength at the ID14-eh2 beamline of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) with a MAR-Research CCD (charge-coupled-device) detector. All data sets were processed with XDS and the structures were solved by use of the CCP4 suite [18] . An initial solution model was determined by molecular replacement with MolRep [19] , starting with the recombinant hBChE structure (PDB entry 1P0I) from which all ligands (butyrate, glycerol, ions) and glycan chains were removed. For all diffraction data sets, the model was refined as follows: an initial rigid-body refinement with REFMAC5 [20] was followed by iterative cycles of model building with Coot [21] , and finally restrained refinement was carried out with REFMAC5 and Phenix [22] . The covalently-bound inhibitors and their descriptions were built using the Dundee PRODRG2.5 server including energy minimization using the GROMOS96.1 forcefield. 
RESULTS
Inhibition of hBChE by tabun analogues
The bimolecular rate constants, k i , for inhibition of human BChE by tabun and its analogues (TA1-TA6) in the absence of substrate are in Table 1 . Phosphoramidocyanidates react faster than homologous phosphoramidofluoridate: TA1 with cyanide as leaving group reacts 17 times faster than TA1 with fluoride as leaving group. Therefore the inhibitory potency was related to the chain length of the N-alkyl group. With tabun and its closest analogues, TA1 and TA2, bearing a cyanide leaving group and dialkyl chains, k i values decreased with increasing chain length. In contrast, for TA4, TA5 and TA6, bearing a mono-N-alkyl group, the inhibitory potency increased with chain length, each carbon addition doubling the bimolecular rate constant.
Determination of enantioselectivity
The time dependence of the inhibition of hBChE by TA4, TA5 and TA6, under second-order conditions, is shown in Figure 3 . Fitting the data to equation 2 yields ki = 2.4 + − 0.2×10 6 M −1 · min −1 and n = 1.8 + − 0.1 for TA4, ki = 8.4 + − 0.5×10 6 M −1 · min −1 and n = 2.0 + − 0.1 for TA5, and ki = 24 + − 2×10 6 M −1 · min −1 and n = 2.0 + − 0.1 for TA6. It follows that hBChE reacts preferentially with one enantiomer of tabun analogues. A similar enantiomeric preference was observed for inhibition of hBChE by tabun [11] . In this regard, ki differs from ki because it is determined under pseudo first-order conditions and describes the reaction of both enantiomers. Moreover, experimental conditions concerning temperature, pH and propan-2-ol-concentration were different.
Reactivation of phosphoramidate-inhibited hBChE by oximes
The reactivation of OP-inhibited hBChE by oximes was tested with 1 mM obidoxime, TMB-4, HI-6 and HLö 7 (Figure 4) . Tabun-inhibited hBChE could be partially reactivated by oximes, and the extent of reactivation decreased in the order obidoxime > TMB-4 > HLö 7> HI-6. Oxime-induced reactivation was rather ineffective with hBChE inhibited by TA1 and TA2. Interestingly, reactivation of hBChE inhibited by TA3 followed a different pattern. All oximes were capable of reactivating the inhibited enzyme, and after a 120 min incubation the recovery in hBChE activity was in the range of 60-85 %.
In contrast, all oximes reactivated hBChE inhibited by N-monoalkyl tabun analogues, i.e. TA4, TA5 and TA6 completely, although there were some differences between oximes regarding velocity and extent of reactivation (Figure 4) .
The reactivation kinetics of hBChE inhibited by tabun and its analogues TA3-TA6 were determined with obidoxime. The reactivation constants are given in Table 1 . K d is the dissociation constant of the oxime-OP-hBChE complex, k r the reactivation constant and k r2 describes the specific reactivity. No rate constants could be determined with hBChE inhibited by TA1 and TA2, due to the low reactivation extent. TA3-inhibited hBChE was, compared with tabun, substantially more susceptible towards reactivation.
The reactivation of hBChE inhibited by N-monoalkyl tabun analogues, TA4, TA5 and TA6, resulted in comparable secondorder rate constants k r2 (Table 1) . There was only a small difference in K d and k r between TA5 and TA6, and both values were substantially lower with TA4.
Aging and spontaneous reactivation of phosphoramidate-inhibited hBChE
Aging and spontaneous reactivation constants are given in Table 1 . The kinetics of aging were not determined for TA1 and TA2 due to the insufficient reactivation extent by oximes. Tabun and its N,Ndi-i-propyl analogue (TA3) showed comparable aging kinetics, with k a values of 0.1 h −1 and 0.094 h −1 respectively. hBChE inhibited by the N-monoalkyl tabun analogues TA4, TA5 and TA6 was susceptible towards aging and spontaneous reactivation. Therefore the velocity of spontaneous reactivation increased with the chain length of the N-alkyl group, whereas the aging rates are comparable and noticeably slower than for tabun-inhibited hBChE (Table 1 ).
Figure 3 Irreversible inhibition of hBChE by racemic tabun analogues performed under second-order conditions
hBChE (29, 32.5 and 30 nM) was inhibited by various concentrations of TA4, TA5 and TA6 respectively, and the residual enzyme activity was monitored as a function of time.
X-ray structures of non-aged tabun analogue-hBChE conjugates
Data were collected from tetragonal crystals of space group I422 and refined to 2.3 Å, 2.15 Å, 2.1 Å and 2.1 Å for TA1, TA4, TA5 and TA6 respectively. Corresponding data and refinement statistics are shown in Table 2 . A strong peak of positive electron density (10-15 σ ) within covalent bond distance of the catalytic serine was observed in the initial |Fo|-|Fc| map for each conjugate. This confirms that inhibitors were bound to the active site serine after 5 min of soaking. The refinement yields an adduct that exhibits P(R) stereochemistry for the chiral phosphorus atom, except for TA4 that exhibits P(S) stereochemistry ( Figure 5 ). Given the good resolution (2.15 Å) and the map quality, there is no ambiguity in TA4 stereochemistry assignment. As a control, we also modelled the presumably incorrect stereoisomer of TA4 and performed one round of structural refinement. Distinct positive and negative difference density (|Fo| -|Fc| map) peaks support the conclusion that the adduct intermediate observed in the structures is in the S conformation. There was no significant movement of residue side-chains compared with the native enzyme (PDB code: 1P0I).
There is a strong peak of positive electron density in the initial |Fo| -|Fc| map close to Trp 82 . This density could not be reasonably modelled. It is most likely due to the presence of the small ligand that was previously observed in other structures of hBChE [23, 24] . This unknown ligand appears stacked against Trp 82 and interacts with water molecules. For TA1 there is no large blob of density, but electron density corresponding to two water molecules. The phosphorus atoms were found at covalent bonding distance from the Ser 198 Oγ atoms (approx. 1.6 Å) and the P-N distance was refined to values ranging from 1.6 Å to 1.7 Å. O 2 of the phosphoramidate moiety is at hydrogen-bonding distance of the main chain amide nitrogen of residues forming the oxyanion hole (Ala 199 /Gly 116 /Gly 117 ). The N-alkyl subsituents were located in the acyl-binding pocket with the alkyl groups pointing towards the top of the gorge, except for TA4. For the latter, the N-alkyl group projects towards the choline-binding pocket, and the ethoxy moiety, located in the acyl-binding pocket, weakly interacts with 
X-ray structure of aged tabun analogue-hBChE conjugates
The structures of aged forms were obtained by crystallization of inhibited enzyme in solution. X-ray crystallographic data were collected from tetragonal crystals of space group I422, except for TA5 (P4212), and refined to 2.25 Å, 2.0 Å and 3.1 Å for TA1, TA4 and TA5 respectively. Corresponding data and refinement statistics are shown in Table 3 . The orientation of aged conjugates is identical to the non-aged conjugates and confirms that the stereoselectivity of the inhibition is identical in cristallo and in solution ( Figure 5 ). This also confirms the initial stereochemistry of TA4. As expected in aged forms, the alkyl group projecting towards the choline-binding pocket is missing. This shows that TA1 and TA5 undergo classical O-dealkylation as previously observed for tabun [11] , phosphates and phosphonates [8] . On the other hand, TA4 probably undergoes deamination. 
, where I is the observed intensity and <I> is the average intensity obtained from multiple observations of symmetry-related reflections after rejections. †R-factor = |Fo-|Fc||/ |Fo|, Fo and Fc are observed and and calculated structure factors. ‡R-free set uses approx. 1000 of randomly chosen reflections.
Figure 5 Active site of non-aged and aged TA-hBChE conjugates
Key residues are represented as sticks with carbon in green for OP and dark blue for hBChE residues, nitrogen atoms in blue, oxygen atoms in red and phosphorus atom in orange. Water molecules are represented by red spheres and hydrogen bonds by red dashes. Electron density 2|Fo| -|Fc| is represented by a blue mesh, contoured at 1.0 σ and |Fo| -|Fc| is represented by green/red mesh contoured at 3.5 σ . 
, where I is the observed intensity and <I> is the average intensity obtained from multiple observations of symmetry-related reflections after rejections.
†R-factor = |Fo-|Fc||/ |Fo|, Fo and Fc are observed and calculated structure factors. ‡R-free set uses approx. 1000 of randomly chosen reflections.
DISCUSSION
The higher inhibitory potency of phosphoramidocyanidates compared with homologous phosphoramidofluoridates (Table 1) could be related to the electron-withdrawing effect of cyanide that is stronger than that of fluorine. Cyanide is also a mesomer acceptor in contrast with fluorine. It follows that the phosphorus atom of phosphoramidocyanidates is more electrophilic and more reactive. It is also possible that, during the approach of the inhibitor, the cyanide substituent makes more favourable interactions with the enzyme than does fluorine. Non-aged and aged structures were obtained for the tabun analogues TA1, TA4, TA5 and non-aged structures for TA6 ( Figure 5 ). We failed to obtain conjugates with TA3 and TA2, most likely because of their poor reactivity with hBChE in relation to their large size. The X-ray structures and second order kinetic data show that there is enantioselectivity for reaction with fluorophosphoramidate analogues (Figures 3 and 5) .
We observed that the N,N-dialkyl substituent of TA1 is located in the acyl-binding pocket, similarly to tabun [11] . The bulky N,N-diethyl substituent of TA1 fits in the acyl-binding pocket, only inducing slight rotation of Leu 286 , and the phosphoramidate head is pushed toward the choline-binding pocket compared with TA5 and TA6 ( Figure 6 ). The steric hindrance resulting from the N,N-diethyl group forces the O-ethoxy substituent to orientate towards the bottom of the choline-binding pocket. This notably prevents the binding of the unknown ligand, just leaving enough room for two water molecules (Figures 5 and 6 ). As for tabun, the orientation of TA1 is explained by delocalization of the N-lone pair and subsequent cation-π interactions between the diethylamino and Trp 231 . For N-monoalkyl analogues (TA4-TA6), the orientation of the OP follows different rules. The larger substituent, whether the ethoxy or amino group, is located in the acyl-binding pocket, forming more van der Waals interactions than the smaller substituent and suggesting that cation-π interactions of the N- monoalkyl group and Trp 231 are secondary in importance. Indeed, we expect weaker cation-π interactions because delocalization of the nitrogen lone pair is less stabilized for primary amines compared with secondary amines, thus leading to a lesser positive partial charge on the amino group. For the N-monoalkyl analogues, the optimal length of the alkylamino or ethoxy substituent appears to be of prime importance for preferential interaction with the acyl-binding pocket. Actually, this could result from the preference of hBChE's acyl-binding pocket for larger than 2-atoms linear substituents. Indeed, when the substituent is shorter, for example a single atom, as for soman-aged hBChE conjugate (PDB code: 1p0q), it induces a rearrangement of the acyl-loop (Val 279 -Asn 289 ). Thus for TA4, the O-ethyl (3-atom chain) substituent is located in the acyl-binding pocket and the shorter N-methyl (2-atom chain) towards the choline-binding pocket ( Figure 5 ).
For TA5, we cannot conclude regarding the orientation, as both substituents are indistinguishable by X-ray crystallography. However, second order kinetics shows that hBChE reacts specifically with one enantiomer of TA5. Since van der Waals interactions should be equivalent for both substituents, we suppose that the ethylamino group interacts preferably with Trp 231 through cation-π interactions, whereas the ethoxy oxygen interacts with His 438 Nε2. Crystallographic data show that aging occurs through classical O-dealkylation for TA1, TA6 ( Figure 5 ), similarly to previous observations made on tabun-ChE conjugates [11] . Unexpectedly, there was also aging for TA4, although the ethoxy group is located in the acyl-binding pocket ( Figure 5 ). These results show that aging of phosphoramidates systematically involves departure of the substituent in the choline-binding pocket. The mechanism differs, depending on the nature of the substituent O-alkyl or Nalkyl group (Figure 7 ). When this substituent is the ethoxy, aging proceeds through dealkylation: His 438 imidazolium stabilizes a developing negative charge on the C-O δ− oxygen, and a water molecule activated by Glu 197 attacks the carbocationic centre that appears on the C δ+ -O carbon. This leads to scission of the C-O bond, release of the ethoxy moiety, and subsequent formation of the salt bridge between the phosphorous O 3 -oxygen and the imidazolium. This is illustrated with TA1, TA6 and previous solved structures of aged hBChE inhibited by tabun, soman, iPr 2 P-F (di-isopropyl fluorophosphate) and echothiophate [11, 23, 24] .
For TA4, the N-methyl substituent projects towards the cholinebinding site so that aging proceeds through deamination: His 438 imidazolium protonates the methylamine group. Extremely rapid deamination after nucleophilic attack by water can be assumed Figure 7 Aging mechanisms of phosphoramidyl-hBChE conjugates since a protonated methylamine is an excellent leaving group. This mechanism, similar to dealkylation, leads to the formation of a salt bridge with a short interatomic distance, as shown by the crystal structure (His 438 Nε2 and O 3 = 2.7Å). Remarkably, aging rates of all monoalkyl analogues are comparable despite the difference in mechanism.
N,N-dialkyl compounds are generally less potent inhibitors of hBChE than N-monoalkyl analogues (Table 1) . N,N-dialkyl compounds are less reactive because steric hindrance from the two alkyl side-chains prevents a correct approach of the OP to the catalytic serine. Moreover, the two alkyl chains have an electronreleasing effect that favours delocalization of the nitrogen lone pair on the phosphorus atom, thus decreasing the electrophilicity of the latter. Additionally, Trp 231 could stabilize positive partial charges on the amino group when the dialkylamino substituent is in the acyl-binding pocket, thus further favouring delocalization of the N-lone pair.
The remarkable correlation between the inhibitory potency and the N-monoalkyl chain length is most likely related to increasingly optimized interactions with the acyl-binding pocket as shown by the X-ray structures ( Figure 5) .
The electronic and steric effects have similar influence on the reactivation reaction by oximes of N,N-dialkyl compared with N-monoalkyl compounds (Figure 4) . In addition to the poorer reactivity of the phosphorus atom, the two alkyl side-chains prevent a correct approach of the oxime in the apical position, as illustrated in Figure 6 .
Obidoxime, TMB-4, HLö 7 and HI-6 have a similar efficiency for reactivating each phosphoramidyl-hBChE conjugate. The increase in chain length of N-monoalkyl compounds does not affect the affinity of oximes for hBChE conjugates in contrast with hAChE [7] because the long chain can easily fit in the acylbinding pocket.
These bispyridinium oximes are much less efficient than for phosphoramidyl-hAChE [7] , despite Tyr 124 , which hinders the phosphorus atom of hAChE conjugates for an optimal apical approach, not being conserved in hBChE (Gln 119 ). This is due to a lower affinity of oximes for phosphoramidyl-hBChE conjugates. Indeed, these bispyridinium oximes bind to the peripheral site of hAChE through aromatic stacking and cation-π interactions between one pyridinium moiety and peripheral site residues (Trp 286 , Tyr 124 and Tyr 72 ) [25] . In hBChE, these aromatic residues are not conserved and bispyridinium oximes cannot interact in the same fashion. Considering that the OPs occupy the bottom of the active site gorge, and that the nucleophile function must be in the apical position for optimal in-line attack, efficient reactivators must bind to the gorge entrance of hBChE. Efforts should be pursued in designing such reactivators.
In summary, this work provides a better understanding of inhibition of hBChE by phosphoramidates and aging of the conjugates, and provides a structural basis for rational design by molecular modelling of hBChE-based catalytic bioscavengers and oximes able to reactivate phosphoramidyl-hBChE. Great improvement in prophylaxis, decontamination and treatment of organophosphate poisoning are expected in the near future as hBChE is close to FDA (Food and Drug Administration) approval.
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